Cytosorbents Corporation, a Delaware-based company, has received an Extension Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. This notice grants the company a 180-day extension, until September 28, 2026, to regain compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing. The company must ensure that its common stock closes at or above $1.00 per share for at least 10 consecutive trading days to meet this requirement. The extension does not affect the current listing status of the company's common stock on Nasdaq, nor does it alter the company's reporting obligations with the SEC. Previously, on October 2, 2025, Cytosorbents was notified of its non-compliance with the minimum bid price requirement based on the closing bid price over the preceding 30 consecutive business days. The company was initially given until March 31, 2026, to rectify this issue. In light of the extension, Cytosorbents plans to actively monitor its stock price and explore options to regain compliance, which may include a reverse stock split if necessary. However, there is no guarantee that the company will successfully meet the compliance requirements within the extended timeframe, raising concerns about the potential for delisting from Nasdaq if compliance is not achieved.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.